logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11707478 B1

PDFFull Text
Date of Patent:
Jul. 25, 2023

Filed:

Aug. 23, 2017

Method for increasing uridine concentration in blood plasma

Applicant:

N.v. Nutricia, Zoetermeer, NL;

Inventor:

Robert Johan Joseph Hageman, Utrecht, NL;

Assignee:

N.V. Nutricia, Zoetermeer, NL;

Attorneys:

N.V. Nederlandsch Octrooibureau

Catherine A. Shultz

Primary Examiner:

Kevin S Orwig

Int. Cl.
CPC ...
A61K 31/7072 (2006.01); A61K 9/08 (2006.01); A61K 47/12 (2006.01); A61K 9/00 (2006.01); A61K 33/14 (2006.01); A61K 45/06 (2006.01); A61P 7/00 (2006.01); A61K 31/14 (2006.01); A61K 31/202 (2006.01); A61K 31/519 (2006.01); A61K 31/675 (2006.01); A61K 31/7105 (2006.01); A61K 33/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7072 (2013.01); A61K 9/0053 (2013.01); A61K 9/0095 (2013.01); A61K 9/08 (2013.01); A61K 31/14 (2013.01); A61K 31/202 (2013.01); A61K 31/519 (2013.01); A61K 31/675 (2013.01); A61K 31/7105 (2013.01); A61K 33/00 (2013.01); A61K 33/14 (2013.01); A61K 45/06 (2013.01); A61K 47/12 (2013.01); A61P 7/00 (2018.01);
Abstract

The invention pertains to the use of soluble sodium in the manufacture of a composition or kit of parts for (therapeutically) improving and prolonging blood plasma uridine levels and tissue availability of uridine, and/or for treating or preventing impaired blood plasma uridine levels and tissue availability of uridine, and/or for preventing/treating disorders associated with impaired blood plasma and tissue availability of uridine, in a mammal, preferably a human being, by orally co-administering soluble sodium and uridine in a molar ratio of soluble sodium to uridine of more than 1:1, preferably more than 1.5:1, more preferably more than 2:1, even more preferably at least 2.5:1, even more preferably at least 2.8:1, more preferably 3:1-15:1, most preferably 3:1-10:1, particularly 3:1-5:1.

Find Patent Forward Citations

Loading…